Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) therapeutic VEGF-Trap (VEGF-TrapHuPTM) to a human subject diagnosed with an ocular disease, e.g. age-related macular degeneration (AMD) or condition or cancer associated with neovascularization, e.g. metastasised colon cancer, and indicated for treatment with the therapeutic mAb. Delivery may be advantageously accomplished via gene therapy, e.g., by administering a viral vector, preferably AAV8 or variant AAV.7m8, or other DNA expression construct encoding the VEGF-TrapHuPTM to a patient (human subject) diagnosed with an ocular condition or cancer indicated for treatment with the VEGF-Trap to create a permanent depot in a tissue or organ of the patient that continuously supplies the VEGF-TrapHuPTM, i.e., a human-glycosylated transgene product. Alternatively, the VEGF-TrapHuPTM, for example, produced in cultured human cell culture, e.g. in immortalised retinal or liver cells, can be administered to the patient for treatment of the ocular disease or cancer.
